Short answer
Inhibrx Biosciences, Inc. (INBX) filed its Q3 2026 10-Q quarterly report on Nov 13, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $2M with net income of −$39M.
Q3 2026 key financials · XBRL
- Revenue
- $2M
- Net income
- −$39M
- −9.9% YoY · −5.7% QoQ
- Operating margin
- -1586.8%
- EPS (diluted)
- −$2.46
- −7.9% YoY · −5.1% QoQ
Source: XBRL data from the Inhibrx Biosciences, Inc. (INBX) Q3 2026 10-Q on SEC EDGAR. USD.
Inhibrx Biosciences, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $2.0M, versus $0 in Q3 2025, entirely from Pfizer license fee revenue
- Net loss $38.7M versus $35.3M, operating loss $31.7M versus $33.8M
- R&D expense $26.0M, down 9% YoY, while G&A rose to $7.8M from $5.3M
- Cash $199.5M at September 30, 2026, with $177.8M financing inflows including $175.0M debt proceeds
- Outlook: cash sufficient for at least 12 months, but continued losses and higher clinical, manufacturing, and pre-commercialization spending expected
Risk Factors
- Newly added regulatory risk: BIOSECURE Act restricts U.S. government dealings involving designated biotechnology companies of concern
- Most materially updated manufacturing risk: FDA Form 483 observations at both ozekibart contract manufacturers threaten BLA approval
- Clinical risk: Ozekibart BLA may face a Complete Response Letter if manufacturers fail to resolve inspection findings
- Operational risk: Limited third-party manufacturers and no long-term supply agreements increase supply disruption exposure
- Market risk: Unbuilt commercialization infrastructure could impair ozekibart launch execution and reimbursement uptake
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Inhibrx Biosciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.